Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KIFC1 | Q9BW19 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16305856 | 0.91 | GCGR (0.46) | CTSLCTSSMAPTL3MBTL1KIFC1 | |
| SCHEMBL20426087 | 0.91 | CTSL (0.42) | CTSLCTSSMAPTL3MBTL1KIFC1 | |
| SCHEMBL16305720 | 0.85 | GCGR (0.45) | CTSLCTSSMAPTL3MBTL1KIFC1 | |
| SCHEMBL16305719 | 0.84 | GCGR (0.48) | CTSLCTSSMAPTL3MBTL1CTSB | |
| SCHEMBL16305671 | 0.83 | GCGR (0.45) | CTSLCTSSMAPTL3MBTL1KIFC1 | |
| SCHEMBL22384196 | 0.83 | NPC1 (0.41) | CTSLCTSSMAPTL3MBTL1KIFC1 | |
| SCHEMBL16305658 | 0.81 | GCGR (0.45) | CTSLCTSSL3MBTL1KIFC1CTSB | |
| SCHEMBL16305662 | 0.81 | PLG (0.43) | L3MBTL1KIFC1PLG | |
| SCHEMBL22384197 | 0.81 | MCHR1 (0.43) | CTSLCTSSL3MBTL1KIFC1CTSB | |
| SCHEMBL16305857 | 0.81 | GCGR (0.46) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSL 1635/4885CTSS 3233/4885MAPT 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.